Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan

Genomics Commercialization: Drug Timeline The Canadian Biopharmaceutical Industry Technology Roadmap 30%

Stage Percentage Discovery 25 Preclinical 7 Phase I 7 Phase II 11 Phase III 23 Regulatory Approval 12 Phase IV (Post Marketing) 11 Uncategorized 4 R&D Drug Investment by Function Pharmaceutical Research and Manufacturers of America, Annual Membership Survey, 2003 Drug discovery = 25% of R&D costs and 45% of development time. Tools such as genomics, bioinformatics, etc. have had minimal impact on R&D productivity when measured by the number of drugs that have entered clinical trials and moved to regulatory approval.

Genomics Commercialization

Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan